Biotechnology company
Appears in 1 story
Phase 2 results reported; pivotal cohort ongoing
C. difficile infection recurs in roughly a quarter of treated patients, sending many back to the hospital for repeat rounds of antibiotics. Lumen Bioscience's oral biologic LMN-201 cut that recurrence to 9.1% in a randomized Phase 2 trial, versus 55.6% for placebo.
Updated 2 hours ago
No stories match your search
Try a different keyword
How would you like to describe your experience with the app today?
